Early 'Top-Down' Treatment Strategy for Crohn's Disease Significantly Improves Long-Term Patient Outcomes

A study published on September 11, 2026, in The Lancet Gastroenterology & Hepatology, reveals that an early 'top-down' treatment approach for Crohn's disease significantly improves long-term outcomes. The PROFILE trial, which followed over 350 patients for an average of five years, found that those receiving early anti-TNF therapy were two times less likely to experience disease progression or hospital admission, and had a five times lower risk of needing abdominal surgery compared to the standard 'step-up' approach.